There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on NGM Biopharmaceuticals (NGM – Research Report) and Alcon (ALC – Research Report) with bullish sentiments. NGM Biopharmaceuticals (NGM) B.Riley Financial analyst Mayank Mamtani reiterated a Buy rating on NGM Biopharmaceuticals today and set a price target of $8.00. The company's shares closed last Friday at $5.42, close to its 52-week low of $2.92. According to TipRanks.
https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-ngm-biopharmaceuticals-ngm-alcon-alc?utm_source=advfn.com&utm_medium=referral
NGM Biopharmaceuticals (NASDAQ:NGM)
Gráfico Histórico do Ativo
De Mai 2023 até Jun 2023 Click aqui para mais gráficos NGM Biopharmaceuticals.
NGM Biopharmaceuticals (NASDAQ:NGM)
Gráfico Histórico do Ativo
De Jun 2022 até Jun 2023 Click aqui para mais gráficos NGM Biopharmaceuticals.